In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of ...

Sanofi (SNY) announced the immediate adoption of influenza strains selected by the Food and Drug Administration to advance the manufacturing ...

Hoechst and Rhône-Poulenc Rorer were the two companies that merged to form Aventis. Despite Sanofi-Synthélabo’s size, the company found itself forced to partner with larger pharmaceutical ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

Sanofi India Limited, (Previously known as Aventis Pharma Limited) was incorporated in May, 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11 ...

Sanofi estimates that the annual cost for a typical patient will be around $280,000 per year before discounts or rebates, in line with other drugs used to treat rare, chronic diseases.

Note :Financial Information is based on numbers. Note :Financial Information is based on numbers. Note :Financial Information is based on numbers. Note :Financial ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

3 Year-23.11%-23.05% 33.40% 35.28% ...